Aclarion Inc (ACON)

$2.46 -0.08 (-3.15%)
Market Cap 2.17M
Revenue (ttm) 50,000.00
Net Income (ttm) -6.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,980.00%
Debt to Equity Ratio 0.00
Volume 30,755
Avg Vol 1,054,170
Day's Range N/A - N/A
Shares Out 854,000.00
Stochastic %K 30%
Beta 1.44
Analysts Sell
Price Target $23.00

Company Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs whi...

Industry: Health Information Services
Sector: Healthcare
Phone: 833 275 2266
Address:
8181 Arista Place, Suite 100, Broomfield, United States
Stock_Catcher
Stock_Catcher Feb. 20 at 2:59 AM
Fortune Friday Watchlist Pt. 9 $ONDS $BULL $NIO $SGN $ACON Let's Feast Bulls
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 8:06 PM
$ACON Current Stock Price: $2.54
0 · Reply
chart_thirst
chart_thirst Feb. 15 at 5:44 AM
$ACON Micro-cap medical device company with near-total revenue collapse; recent 1:16 reverse split and sub-$1M market cap signal distress.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 11:57 PM
$ACON RSI: 21.05, MACD: -0.6405 Vol: 0.55, MA20: 3.27, MA50: 4.77 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Trtrucking79
Trtrucking79 Feb. 10 at 5:48 AM
$ACON 🤷
0 · Reply
TapeWatcher
TapeWatcher Feb. 9 at 12:48 PM
$ACON is a consulting or professional services firm; project-based revenue is vulnerable to client budget cuts during economic uncertainty.
0 · Reply
Putnik
Putnik Feb. 6 at 8:55 PM
$ACON this shit needs to run for real!
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 6 at 5:59 PM
$ACON Current Stock Price: $2.55
0 · Reply
biley
biley Feb. 6 at 3:44 PM
$ACON Heads up to reatail! The issue with this one is the 10m pre funded warrant the company issued last month that is equivalent to a synthetic short. The party that owns it has all the power here in determining the price. That is why the volume is so high and insiders dont buy the shares at this seemingly undervalued level.Doesnt mean the stock cant pop but until the owner of the warrant reaches the 5 or 9.9% threshold which have no idea when or how that factors in, they have all the cards. Bottom line be careful, if want trade it but management really screwed the shareholder base here. Company went public too early. Good luck!
2 · Reply
Inlowouthigh
Inlowouthigh Feb. 6 at 4:05 AM
$ACON $AGRZ $NITO $TAOP $TAOX hey slope. Same post on a dozen tickers won’t make anyone believe your nonsense. Take your 10 shares you were paid to pump, and your,lol, 12 followers, and piss off
0 · Reply
Latest News on ACON
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Dec 2, 2025, 8:00 AM EST - 2 months ago

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 22, 2025, 6:00 AM EDT - 4 months ago

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Aclarion to Present at the LD Micro Main Event XIX

Oct 9, 2025, 6:00 AM EDT - 4 months ago

Aclarion to Present at the LD Micro Main Event XIX

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Jun 24, 2025, 7:00 AM EDT - 8 months ago

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 20, 2025, 6:00 AM EDT - 9 months ago

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

May 12, 2025, 7:34 AM EDT - 10 months ago

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 29, 2025, 6:00 AM EDT - 10 months ago

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Apr 23, 2025, 6:00 AM EDT - 10 months ago

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 21, 2025, 6:00 AM EDT - 11 months ago

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Apr 9, 2025, 7:00 AM EDT - 11 months ago

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Apr 2, 2025, 6:00 AM EDT - 11 months ago

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Aclarion Provides Shareholder Update

Mar 13, 2025, 9:25 AM EDT - 1 year ago

Aclarion Provides Shareholder Update

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 6, 2025, 9:35 AM EST - 1 year ago

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Aclarion Announces First Commercial Agreement with Scripps Health

Mar 3, 2025, 6:00 AM EST - 1 year ago

Aclarion Announces First Commercial Agreement with Scripps Health

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Feb 20, 2025, 6:00 AM EST - 1 year ago

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 11, 2025, 7:58 AM EST - 1 year ago

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 6, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Feb 4, 2025, 7:23 AM EST - 1 year ago

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Nov 21, 2024, 8:00 AM EST - 1 year ago

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Nov 14, 2024, 5:00 PM EST - 1 year ago

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Sep 27, 2024, 6:57 AM EDT - 1 year ago

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 13, 2024, 8:30 AM EDT - 1 year ago

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Sep 12, 2024, 6:57 AM EDT - 1 year ago

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Sep 10, 2024, 6:57 AM EDT - 1 year ago

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Sep 5, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aug 29, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aug 21, 2024, 7:57 AM EDT - 1 year ago

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aug 15, 2024, 9:48 AM EDT - 1 year ago

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aclarion Announces First Commercial Agreement in Michigan

Aug 14, 2024, 8:08 AM EDT - 1 year ago

Aclarion Announces First Commercial Agreement in Michigan

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Aug 13, 2024, 9:07 AM EDT - 1 year ago

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Jun 26, 2024, 8:30 AM EDT - 1 year ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Apr 25, 2024, 9:14 AM EDT - 1 year ago

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Aclarion Announces Closing of $3.0 Million Public Offering

Feb 27, 2024, 3:22 PM EST - 2 years ago

Aclarion Announces Closing of $3.0 Million Public Offering

Aclarion Announces Pricing of $3.0 Million Public Offering

Feb 26, 2024, 9:15 AM EST - 2 years ago

Aclarion Announces Pricing of $3.0 Million Public Offering

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Feb 5, 2024, 8:00 AM EST - 2 years ago

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Jan 22, 2024, 8:00 AM EST - 2 years ago

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Nov 27, 2023, 8:00 AM EST - 2 years ago

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Nov 6, 2023, 8:00 AM EST - 2 years ago

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Oct 25, 2023, 8:30 AM EDT - 2 years ago

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Oct 24, 2023, 8:45 AM EDT - 2 years ago

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

Aug 25, 2023, 4:10 PM EDT - 2 years ago

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

Jun 14, 2023, 11:27 AM EDT - 2 years ago

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

Jun 8, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

May 30, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

May 23, 2023, 7:30 AM EDT - 2 years ago

Aclarion's Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD

Stock_Catcher
Stock_Catcher Feb. 20 at 2:59 AM
Fortune Friday Watchlist Pt. 9 $ONDS $BULL $NIO $SGN $ACON Let's Feast Bulls
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 17 at 8:06 PM
$ACON Current Stock Price: $2.54
0 · Reply
chart_thirst
chart_thirst Feb. 15 at 5:44 AM
$ACON Micro-cap medical device company with near-total revenue collapse; recent 1:16 reverse split and sub-$1M market cap signal distress.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 11:57 PM
$ACON RSI: 21.05, MACD: -0.6405 Vol: 0.55, MA20: 3.27, MA50: 4.77 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Trtrucking79
Trtrucking79 Feb. 10 at 5:48 AM
$ACON 🤷
0 · Reply
TapeWatcher
TapeWatcher Feb. 9 at 12:48 PM
$ACON is a consulting or professional services firm; project-based revenue is vulnerable to client budget cuts during economic uncertainty.
0 · Reply
Putnik
Putnik Feb. 6 at 8:55 PM
$ACON this shit needs to run for real!
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 6 at 5:59 PM
$ACON Current Stock Price: $2.55
0 · Reply
biley
biley Feb. 6 at 3:44 PM
$ACON Heads up to reatail! The issue with this one is the 10m pre funded warrant the company issued last month that is equivalent to a synthetic short. The party that owns it has all the power here in determining the price. That is why the volume is so high and insiders dont buy the shares at this seemingly undervalued level.Doesnt mean the stock cant pop but until the owner of the warrant reaches the 5 or 9.9% threshold which have no idea when or how that factors in, they have all the cards. Bottom line be careful, if want trade it but management really screwed the shareholder base here. Company went public too early. Good luck!
2 · Reply
Inlowouthigh
Inlowouthigh Feb. 6 at 4:05 AM
$ACON $AGRZ $NITO $TAOP $TAOX hey slope. Same post on a dozen tickers won’t make anyone believe your nonsense. Take your 10 shares you were paid to pump, and your,lol, 12 followers, and piss off
0 · Reply
Huskersnsaints
Huskersnsaints Feb. 5 at 9:46 PM
$ACON i have to be live this is now over sold huge low volume drop this last week WTF
0 · Reply
OneSmarTrader
OneSmarTrader Feb. 5 at 8:35 PM
$ACON Just added to my holdings.
0 · Reply
Apes_Strong
Apes_Strong Feb. 5 at 8:18 PM
$ACON the problem with criminals at the helm You can’t even give away cash at a 63% discount
0 · Reply
KuruHabesha
KuruHabesha Feb. 5 at 7:31 PM
$ACON No brainer, adding!
0 · Reply
OneSmarTrader
OneSmarTrader Feb. 5 at 3:34 PM
$ACON
0 · Reply
DonZulu
DonZulu Feb. 5 at 3:11 PM
$ACON 22 million cash on hand sitting at low lows we should see upside into 10$
0 · Reply
NewbieMoveOver
NewbieMoveOver Feb. 5 at 2:55 PM
$ACON well this is nice of them
0 · Reply
Huskersnsaints
Huskersnsaints Feb. 5 at 2:43 PM
$ACON well CEO SAID NO MORE DILUTION AND OUSTANDING IS 2.9 million not horrible but I believe they are sitting on a market cap now 7.8 million Not sure of cash position but i think its roughly $15 million
0 · Reply
KuruHabesha
KuruHabesha Feb. 5 at 1:36 PM
$ACON It is time!
0 · Reply
PatentGrants
PatentGrants Feb. 4 at 8:56 PM
$ACON Aclarion has been granted European patent number EP4289347 titled "MAGNETIC RESONANCE SPECTROSCOPY SYSTEM AND METHOD FOR DIAGNOSING PAIN OR INFECTION ASSOCIATED WITH PROPIONIC ACID". https://data.epo.org/publication-server/publications/pdf?path=2026/06/DOC/EPNWB1/EP23192377NWB1/EP23192377NWB1.pdf
0 · Reply
DonZulu
DonZulu Feb. 4 at 6:35 PM
$ACON 5-7$ from here
0 · Reply
Putnik
Putnik Feb. 4 at 6:20 PM
$ACON averaged Down under $10 I was hoping this goes to $15 but I think even breaking even would make me happy now
0 · Reply